ReviewTherapeutic advances in musculoskeletal disease2019
Glucocorticoid-induced osteoporosis: from clinical trials to clinical practice.
Review in Therapeutic advances in musculoskeletal disease, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Animal Model for Glucocorticoid Induced Osteoporosis: A Systematic Review from 2011 to 2021.International journal of molecular sciences · 2021Pooled it
- Radiofrequency Echographic Multi Spectrometry (REMS) for the evaluation of bone health in systemic lupus erythematosus (SLE).Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026Article
- Antiresorptive treatments for corticosteroid-induced osteoporosis: a Bayesian network meta-analysis.British medical bulletin · 2022Article
- The RNA-binding protein Musashi2 governs osteoblast-adipocyte lineage commitment by suppressing PPARγ signaling.Bone research · 2022Article
- Real-life short-term effectiveness of anti-osteoporotic treatments: a longitudinal cohort study.Therapeutic advances in musculoskeletal disease · 2022Article
- Comprehensive circRNA Analyses in Human Vertebrae of GIOP and Its Molecular Mechanism.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- German Society of Rheumatology recommendations for management of glucocorticoid-induced osteoporosis.Zeitschrift fur Rheumatologie · 2021Review
- [German Society of Rheumatology Recommendations for the management of glucocorticoid-induced Osteoporosis. German version].Zeitschrift fur Rheumatologie · 2021Review
- Metabolic Disorders and Mineral Density of the Bone Tissue in the Early Pathogenesis of Osteonecrosis: Study on Rabbits with Steroid-Induced Osteonecrosis.Bulletin of experimental biology and medicine · 2021Article
- Mechanisms of Bone Fragility: From Osteogenesis Imperfecta to Secondary Osteoporosis.International journal of molecular sciences · 2021Review
- Evaluation of risk factors of vertebral fracture in Japanese female patients with glucocorticoid-induced osteoporosis.Journal of orthopaedic surgery and research · 2020Article
- Osteoporosis in Rheumatic Diseases.International journal of molecular sciences · 2019Review
- Glucocorticoids and Trabecular Bone Score.Journal of medicine and lifeReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glucocorticoid-induced osteoporosis (GIOP) is the most common form of secondary osteoporosis. To date, six large randomized controlled clinical trials on the efficacy of pharmaceutical treatment in GIOP have been conducted. All of these studies have focused predominately on bone mineral density outcomes, and none of them have been statistically powered to address fracture endpoints. The purpose of this review is to highlight differences in the design and results within these large randomized GIOP clinical trials, and how these differences might affect clinical decisions. Differences between studies in trial design, populations studied, and variable efficacy impact the comparability and generalizability of these findings, and ultimately should affect practitioners' behavior. We review the clinical trials that provide the best quality evidence on comparative efficacy and safety of GIOP treatments. We also propose suggestions on the design of future GIOP clinical trials with attention to improved generalizability, and, ideally, study designs that might achieve fracture outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.